DEFA14A: Veru Inc. Adjourns 2024 Annual Meeting of Shareholders Due to Lack of Quorum

Veru Inc. has adjourned its 2024 Annual Meeting of Shareholders to June 27, 2024, due to the absence of a quorum.

Summary

• Veru Inc. adjourned its Annual Meeting of Shareholders, originally scheduled for June 18, 2024, due to a lack of the required quorum.
• The meeting has been rescheduled for June 27, 2024, at 9:00 a.m. local time, at 2916 N. Miami Avenue, Suite 1000, Miami, Florida 33127.
• The agenda for the adjourned meeting remains the same as described in the amended definitive proxy statement filed on May 9, 2024.
• At the time of adjournment, proxies representing approximately 49.6% of the company's outstanding common stock had been submitted, falling short of the majority required for a quorum.
• The record date for the adjourned Annual Meeting remains April 29, 2024.
• Shareholders who have already submitted proxies do not need to take further action unless they wish to revoke their previous vote.
• Veru encourages shareholders to vote to ensure the company reaches a quorum and avoids costly procedures.
• Veru is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS.
• The company's drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin.
• Enobosarm is in Phase 2b clinical study as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA and, subject to funding, Phase 3 ENABLAR-2 clinical trial for metastatic breast cancer.
• Sabizabulin is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS, but further development is contingent on securing external funding.
• The company also has an FDA-approved commercial product, the FC2 Female Condom.

Sentiment

Score: 5

Explanation: The announcement is neutral, primarily conveying information about the adjournment of the annual meeting. The company's future prospects are mentioned, but are balanced with risks and uncertainties.

Positives

• Veru is actively developing enobosarm for significant indications like obesity and metastatic breast cancer.
• The company has an existing FDA-approved product, the FC2 Female Condom, providing a revenue stream.
• Veru is exploring strategic partnerships and government grants to fund the development of sabizabulin.

Negatives

• The Annual Meeting was adjourned due to a lack of quorum, indicating potential shareholder engagement issues.
• Development of sabizabulin for ARDS is contingent on securing external funding, creating uncertainty.
• The company acknowledges risks related to clinical trial success, regulatory approvals, and market competition.

Risks

• Clinical trials for enobosarm and sabizabulin may not be successful or meet regulatory standards.
• The company may face challenges in enrolling sufficient subjects in clinical studies.
• Securing sufficient funding for planned clinical development and operations is a risk.
• The company's products may not achieve commercial success.
• Veru faces competition from companies with greater resources and new product approvals.
• Changes in regulatory practices or healthcare reform efforts could impact the company.
• The company's reliance on international partners and government spending in the global public sector poses risks.
• Production capacity, efficiency, and supply constraints could disrupt operations.
• Litigation, including product liability claims and securities litigation, could have adverse effects.
• The company's ability to protect and enforce its intellectual property is a risk.

Future Outlook

Veru aims to transform into a late-stage biopharmaceutical company focused on obesity and oncology, contingent on the success of its clinical trials and securing necessary funding.

Industry Context

Veru is operating in the competitive biopharmaceutical industry, focusing on oncology, metabolic diseases, and ARDS, areas with significant unmet medical needs and potential market opportunities. The company's success depends on its ability to navigate regulatory hurdles, secure funding, and demonstrate clinical efficacy.

Stakeholder Impact

• Shareholders are impacted by the delay of the Annual Meeting and are encouraged to vote.
• Employees are affected by the company's strategic direction and the progress of its drug development programs.
• Patients could benefit from the successful development of new treatments for obesity, cancer, and ARDS.

Next Steps

• Shareholders are encouraged to vote on the proposals outlined in the proxy statement.
• Veru will proceed with the adjourned Annual Meeting on June 27, 2024.
• The company will continue to pursue clinical development of enobosarm and seek funding for sabizabulin.

Key Dates

Keywords

Veru, Annual Meeting, Shareholders, Quorum, Enobosarm, Sabizabulin, FC2 Female Condom, Clinical Trials, Biopharmaceutical, Oncology, ARDS, Obesity